Screener / SEC EDGAR /CIK 0001757073 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Dental Equipment & Supplies

Envista Holdings Corp NVST

Compare with peers Embed

NVST among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+8.3%91st of 155 · median +10.5%
Net margin
-4.1%15.3%
22.0%21st of 154 · median 6.8%
Return on equity
-5.2%18.5%
20.5%28th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
8.4%83rd of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.4632nd of 108 · median 0.69

NVST and 9 peers, year by year

The 9 Health care companies closest to NVST in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
NVST Envista Holdings Corp FY2025 $2.7B+8.3%54.7%7.9%1.7%8.5%1.5%0.47
HIMS Hims & Hers Health, Inc. FY2025 $2.3B+59.0%73.8%4.5%5.5%2.4%23.7%-
NTRA Natera, Inc. FY2025 $2.3B+35.9%-−13.4%−9.0%4.7%−12.2%0.05
MEDP Medpace Holdings, Inc. FY2025 $2.5B+20.0%-21.1%17.8%26.9%98.3%-
RVTY Revvity FY2025 $2.9B+3.7%-12.5%8.4%17.8%3.3%0.44
BKD Brookdale Senior Living Inc. FY2025 $3.2B+2.2%26.2%0.4%−8.2%0.5%n/mn/m
CHE Chemed Corp FY2025 $2.5B+4.1%-13.4%10.5%12.9%27.1%-
RPRX Royalty Pharma plc FY2025 $2.4B+5.1%-65.6%32.4%-7.9%0.92
GMED Globus Medical Inc FY2025 $2.9B+16.7%-16.3%18.3%20.0%11.8%-
QDEL QuidelOrtho Corp FY2025 $2.7B−1.9%-−33.7%−41.5%−3.0%−58.9%1.40

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2017 to FY2025 · 10-K XBRL

NVSTEnvista Holdings Corp
FY2017 revenue $2.8BFY2018 revenue $2.8BFY2019 revenue $2.3BFY2020 revenue $1.9BFY2021 revenue $2.5BFY2022 revenue $2.6BFY2023 revenue $2.6BFY2024 revenue $2.5BFY2025 revenue $2.7B FY2017 net margin 10.7%FY2018 net margin 8.1%FY2019 net margin 9.5%FY2020 net margin 1.7%FY2021 net margin 13.6%FY2022 net margin 9.5%FY2023 net margin −3.9%FY2024 net margin −44.6%FY2025 net margin 1.7% FY2017FY2025
Revenue$2.7B Growth+8.3% Net margin1.7%
HIMSHims & Hers Health, Inc.
FY2019 revenue $82.6MFY2020 revenue $148.8MFY2021 revenue $271.9MFY2022 revenue $526.9MFY2023 revenue $872.0MFY2024 revenue $1.5BFY2025 revenue $2.3B FY2019 net margin −87.3%FY2020 net margin −12.2%FY2021 net margin −39.6%FY2022 net margin −12.5%FY2023 net margin −2.7%FY2024 net margin 8.5%FY2025 net margin 5.5% FY2017FY2025
Revenue$2.3B Growth+59.0% Net margin5.5%
NTRANatera, Inc.
FY2017 revenue $210.9MFY2018 revenue $257.7MFY2019 revenue $302.3MFY2020 revenue $391.0MFY2021 revenue $625.5MFY2022 revenue $820.2MFY2023 revenue $1.1BFY2024 revenue $1.7BFY2025 revenue $2.3B FY2017 net margin −65.2%FY2018 net margin −49.7%FY2019 net margin −41.3%FY2020 net margin −58.8%FY2021 net margin −75.4%FY2022 net margin −66.8%FY2023 net margin −40.2%FY2024 net margin −11.2%FY2025 net margin −9.0% FY2017FY2025
Revenue$2.3B Growth+35.9% Net margin−9.0%
MEDPMedpace Holdings, Inc.
FY2017 revenue $436.2MFY2018 revenue $704.6MFY2019 revenue $861.0MFY2020 revenue $925.9MFY2021 revenue $1.1BFY2022 revenue $1.5BFY2023 revenue $1.9BFY2024 revenue $2.1BFY2025 revenue $2.5B FY2017 net margin 9.0%FY2018 net margin 10.4%FY2019 net margin 11.7%FY2020 net margin 15.7%FY2021 net margin 15.9%FY2022 net margin 16.8%FY2023 net margin 15.0%FY2024 net margin 19.2%FY2025 net margin 17.8% FY2017FY2025
Revenue$2.5B Growth+20.0% Net margin17.8%
RVTYRevvity
FY2017 revenue $2.3BFY2018 revenue $2.8BFY2019 revenue $2.9BFY2020 revenue $3.8BFY2021 revenue $3.8BFY2022 revenue $3.3BFY2023 revenue $2.8BFY2024 revenue $2.8BFY2025 revenue $2.9B FY2017 net margin 13.0%FY2018 net margin 8.6%FY2019 net margin 7.9%FY2020 net margin 19.2%FY2021 net margin 24.6%FY2022 net margin 17.2%FY2023 net margin 25.2%FY2024 net margin 9.8%FY2025 net margin 8.4% FY2017FY2025
Revenue$2.9B Growth+3.7% Net margin8.4%
BKDBrookdale Senior Living Inc.
FY2017 revenue $4.7BFY2018 revenue $4.5BFY2019 revenue $4.1BFY2020 revenue $3.5BFY2021 revenue $2.8BFY2022 revenue $2.8BFY2023 revenue $3.0BFY2024 revenue $3.1BFY2025 revenue $3.2B FY2017 net margin −12.0%FY2018 net margin −11.7%FY2019 net margin −6.6%FY2020 net margin 2.3%FY2021 net margin −3.6%FY2022 net margin −8.4%FY2023 net margin −6.3%FY2024 net margin −6.5%FY2025 net margin −8.2% FY2017FY2025
Revenue$3.2B Growth+2.2% Net margin−8.2%
CHEChemed Corp
FY2017 revenue $1.7BFY2018 revenue $1.8BFY2019 revenue $1.9BFY2020 revenue $2.1BFY2021 revenue $2.1BFY2022 revenue $2.1BFY2023 revenue $2.3BFY2024 revenue $2.4BFY2025 revenue $2.5B FY2017 net margin 5.9%FY2018 net margin 11.5%FY2019 net margin 11.3%FY2020 net margin 15.4%FY2021 net margin 12.6%FY2022 net margin 11.7%FY2023 net margin 12.0%FY2024 net margin 12.4%FY2025 net margin 10.5% FY2017FY2025
Revenue$2.5B Growth+4.1% Net margin10.5%
RPRXRoyalty Pharma plc
FY2018 revenue $1.8BFY2019 revenue $1.8BFY2020 revenue $2.1BFY2021 revenue $2.3BFY2022 revenue $2.2BFY2023 revenue $2.4BFY2024 revenue $2.3BFY2025 revenue $2.4B FY2018 net margin 76.8%FY2019 net margin 129.4%FY2020 net margin 45.9%FY2021 net margin 27.1%FY2022 net margin 1.9%FY2023 net margin 48.2%FY2024 net margin 37.9%FY2025 net margin 32.4% FY2017FY2025
Revenue$2.4B Growth+5.1% Net margin32.4%
GMEDGlobus Medical Inc
FY2017 revenue $636.0MFY2018 revenue $713.0MFY2019 revenue $785.4MFY2020 revenue $789.0MFY2021 revenue $958.1MFY2022 revenue $1.0BFY2023 revenue $1.6BFY2024 revenue $2.5BFY2025 revenue $2.9B FY2017 net margin 16.9%FY2018 net margin 21.9%FY2019 net margin 19.8%FY2020 net margin 13.0%FY2021 net margin 15.6%FY2022 net margin 18.6%FY2023 net margin 7.8%FY2024 net margin 4.1%FY2025 net margin 18.3% FY2017FY2025
Revenue$2.9B Growth+16.7% Net margin18.3%
QDELQuidelOrtho Corp
FY2020 revenue $1.7BFY2021 revenue $1.7BFY2022 revenue $3.3BFY2023 revenue $3.0BFY2024 revenue $2.8BFY2025 revenue $2.7B FY2020 net margin 48.8%FY2021 net margin 41.5%FY2022 net margin 16.8%FY2023 net margin −0.3%FY2024 net margin −73.7%FY2025 net margin −41.5% FY2017FY2025
Revenue$2.7B Growth−1.9% Net margin−41.5%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2017 to FY2025

Revenue as reported in the 10-K.

100 200 500 1000 2000 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, -, $82.6M, $148.8M, $271.9M, $526.9M, $872.0M, $1.5B, $2.3B HIMS NTRA: $210.9M, $257.7M, $302.3M, $391.0M, $625.5M, $820.2M, $1.1B, $1.7B, $2.3B NTRA MEDP: $436.2M, $704.6M, $861.0M, $925.9M, $1.1B, $1.5B, $1.9B, $2.1B, $2.5B MEDP RVTY: $2.3B, $2.8B, $2.9B, $3.8B, $3.8B, $3.3B, $2.8B, $2.8B, $2.9B RVTY BKD: $4.7B, $4.5B, $4.1B, $3.5B, $2.8B, $2.8B, $3.0B, $3.1B, $3.2B BKD CHE: $1.7B, $1.8B, $1.9B, $2.1B, $2.1B, $2.1B, $2.3B, $2.4B, $2.5B CHE RPRX: -, $1.8B, $1.8B, $2.1B, $2.3B, $2.2B, $2.4B, $2.3B, $2.4B RPRX GMED: $636.0M, $713.0M, $785.4M, $789.0M, $958.1M, $1.0B, $1.6B, $2.5B, $2.9B GMED QDEL: -, -, -, $1.7B, $1.7B, $3.3B, $3.0B, $2.8B, $2.7B QDEL NVST: $2.8B, $2.8B, $2.3B, $1.9B, $2.5B, $2.6B, $2.6B, $2.5B, $2.7B NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. Each company's first year in the window is 100, on a log scale: a line twice as high has doubled. A gap is a year with no number. A ring marks where a line starts: HIMS, RPRX, QDEL have no earlier 10-K here. NVST: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2017 to FY2025

Revenue against the fiscal year before.

−22.1% +93.8% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, -, -, +80.2%, +82.8%, +93.8%, +65.5%, +69.3%, +59.0% HIMS NTRA: −1.4%, +22.9%, +17.3%, +29.3%, +60.0%, +31.1%, +32.0%, +56.7%, +35.9% NTRA MEDP: +3.5%, +61.5%, +22.2%, +7.5%, +23.4%, +27.8%, +29.2%, +11.8%, +20.0% MEDP RVTY: +6.7%, +23.1%, +3.8%, +31.2%, +43.7%, −13.5%, −16.9%, +0.2%, +3.7% RVTY BKD: −4.6%, −4.5%, −10.5%, −12.7%, −22.1%, +2.4%, +6.7%, +3.6%, +2.2% BKD CHE: +5.7%, +7.0%, +7.0%, +4.2%, −5.5%, −4.7%, +9.4%, +7.4%, +4.1% CHE RPRX: -, -, +1.1%, +17.0%, +7.9%, −2.3%, +5.2%, −3.9%, +5.1% RPRX GMED: +12.8%, +12.1%, +10.2%, +0.5%, +21.4%, +6.8%, +53.3%, +60.6%, +16.7% GMED QDEL: -, -, -, -, +2.2%, +92.3%, −8.2%, −7.2%, −1.9% QDEL NVST: -, +1.2%, −3.3%, −15.6%, +30.1%, +2.4%, −0.1%, −2.2%, +8.3% NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −22.1% to +93.8%. A gap is a year with no number. A ring marks where a line starts: NVST, HIMS, RPRX, QDEL have no earlier 10-K here.

Gross margin, FY2017 to FY2025

Gross profit / revenue.

18.2% 82.0% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, -, 54.0%, 73.6%, 75.2%, 77.6%, 82.0%, 79.5%, 73.8% HIMS RVTY: 47.6%, 48.3%, 48.4%, 55.8%, 63.6%, 60.1%, -, -, - RVTY BKD: 26.4%, 23.6%, 21.6%, 22.5%, 18.2%, 21.0%, 24.8%, 25.6%, 26.2% BKD GMED: 76.3%, 77.6%, 77.1%, 72.4%, 75.0%, 74.2%, 65.1%, -, - GMED NVST: 57.7%, 56.3%, 59.1%, 54.7%, 56.9%, 57.4%, 56.1%, 54.7%, 54.7% NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 18.2% to 82.0%. A gap is a year with no number. A ring marks where a line starts: HIMS has no earlier 10-K here.
CompanyFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
NVST Dec 57.7%56.3%59.1%54.7%56.9%57.4%56.1%54.7%54.7%
HIMS Dec --54.0%73.6%75.2%77.6%82.0%79.5%73.8%
NTRA Dec ---------
MEDP Dec ---------
RVTY Dec 47.6%48.3%48.4%55.8%63.6%60.1%---
BKD Dec 26.4%23.6%21.6%22.5%18.2%21.0%24.8%25.6%26.2%
CHE Dec ---------
RPRX Dec ---------
GMED Dec 76.3%77.6%77.1%72.4%75.0%74.2%65.1%--
QDEL Dec ---------
Peer median47.6%48.3%51.2%64.1%69.3%67.1%65.1%--

Operating margin, FY2017 to FY2025

Operating income / revenue.

−90.1% 144.6% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, -, −90.1%, −10.2%, −42.3%, −13.0%, −3.4%, 4.2%, 4.5% HIMS NTRA: −64.2%, −44.5%, −38.5%, −55.3%, −74.8%, −66.0%, −41.2%, −13.1%, −13.4% NTRA MEDP: 14.9%, 14.3%, 14.8%, 18.0%, 17.4%, 19.1%, 17.9%, 21.2%, 21.1% MEDP RVTY: 13.1%, 11.7%, 12.6%, 22.9%, 32.9%, 22.4%, 10.9%, 12.6%, 12.5% RVTY BKD: −5.7%, −13.1%, −1.1%, −2.8%, −7.9%, −1.5%, 0.6%, 1.5%, 0.4% BKD CHE: 6.8%, 13.7%, 13.3%, 18.7%, 16.0%, 16.1%, 15.0%, 15.1%, 13.4% CHE RPRX: -, 76.0%, 144.6%, 75.2%, 62.5%, 13.7%, 63.4%, 57.1%, 65.6% RPRX GMED: 25.4%, 23.7%, 21.9%, 14.1%, 17.9%, 22.3%, 8.5%, 6.6%, 16.3% GMED QDEL: -, -, -, 63.8%, 53.3%, 25.8%, 4.6%, −70.5%, −33.7% QDEL NVST: 13.8%, 10.5%, 10.3%, 2.3%, 12.2%, 12.4%, 1.2%, −41.4%, 7.9% NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −90.1% to 144.6%. A gap is a year with no number. A ring marks where a line starts: HIMS, RPRX, QDEL have no earlier 10-K here.

Net margin, FY2017 to FY2025

Net income / revenue.

−87.3% 129.4% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, -, −87.3%, −12.2%, −39.6%, −12.5%, −2.7%, 8.5%, 5.5% HIMS NTRA: −65.2%, −49.7%, −41.3%, −58.8%, −75.4%, −66.8%, −40.2%, −11.2%, −9.0% NTRA MEDP: 9.0%, 10.4%, 11.7%, 15.7%, 15.9%, 16.8%, 15.0%, 19.2%, 17.8% MEDP RVTY: 13.0%, 8.6%, 7.9%, 19.2%, 24.6%, 17.2%, 25.2%, 9.8%, 8.4% RVTY BKD: −12.0%, −11.7%, −6.6%, 2.3%, −3.6%, −8.4%, −6.3%, −6.5%, −8.2% BKD CHE: 5.9%, 11.5%, 11.3%, 15.4%, 12.6%, 11.7%, 12.0%, 12.4%, 10.5% CHE RPRX: -, 76.8%, 129.4%, 45.9%, 27.1%, 1.9%, 48.2%, 37.9%, 32.4% RPRX GMED: 16.9%, 21.9%, 19.8%, 13.0%, 15.6%, 18.6%, 7.8%, 4.1%, 18.3% GMED QDEL: -, -, -, 48.8%, 41.5%, 16.8%, −0.3%, −73.7%, −41.5% QDEL NVST: 10.7%, 8.1%, 9.5%, 1.7%, 13.6%, 9.5%, −3.9%, −44.6%, 1.7% NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −87.3% to 129.4%. A gap is a year with no number. A ring marks where a line starts: HIMS, RPRX, QDEL have no earlier 10-K here.

Free cash flow, FY2017 to FY2025

Cash from operations minus capital spending.

−$479.2M $1.3B FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, -, -, -, -, −$33.7M, $47.0M, $198.3M, $57.4M HIMS NTRA: −$107.7M, −$74.5M, −$68.4M, −$202.1M, −$376.3M, −$479.2M, −$286.2M, $69.2M, $109.1M NTRA MEDP: $85.7M, $140.6M, $184.0M, $227.3M, $235.1M, $351.2M, $396.7M, $572.3M, $681.9M MEDP RVTY: $249.4M, $217.8M, $287.1M, $828.5M, $1.3B, $594.2M, $9.9M, $541.7M, $509.4M RVTY BKD: $164.5M, −$21.5M, −$87.7M, $19.8M, −$271.3M, −$193.6M, −$70.3M, −$35.1M, $16.5M BKD CHE: $98.2M, $234.3M, $248.2M, $430.5M, $249.9M, $252.6M, $273.4M, $368.0M, $325.5M CHE GMED: $107.8M, $121.9M, $101.2M, $135.1M, $219.4M, $104.4M, $165.2M, $405.2M, $588.8M GMED QDEL: -, -, -, $564.8M, $513.1M, $744.4M, $70.9M, −$112.1M, −$83.0M QDEL NVST: $310.2M, $327.9M, $319.7M, $236.2M, $306.9M, $107.0M, $217.5M, $302.7M, $230.4M NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$479.2M to $1.3B. A gap is a year with no number. A ring marks where a line starts: HIMS, QDEL have no earlier 10-K here.

FCF margin, FY2017 to FY2025

Free cash flow / revenue.

−60.2% 34.6% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, -, -, -, -, −6.4%, 5.4%, 13.4%, 2.4% HIMS NTRA: −51.1%, −28.9%, −22.6%, −51.7%, −60.2%, −58.4%, −26.4%, 4.1%, 4.7% NTRA MEDP: 19.6%, 19.9%, 21.4%, 24.6%, 20.6%, 24.1%, 21.0%, 27.1%, 26.9% MEDP RVTY: 11.0%, 7.8%, 10.0%, 21.9%, 34.6%, 17.9%, 0.4%, 19.7%, 17.8% RVTY BKD: 3.5%, −0.5%, −2.2%, 0.6%, −9.8%, −6.9%, −2.3%, −1.1%, 0.5% BKD CHE: 5.9%, 13.1%, 12.8%, 20.7%, 11.7%, 11.8%, 12.1%, 15.1%, 12.9% CHE GMED: 16.9%, 17.1%, 12.9%, 17.1%, 22.9%, 10.2%, 10.5%, 16.1%, 20.0% GMED QDEL: -, -, -, 34.0%, 30.2%, 22.8%, 2.4%, −4.0%, −3.0% QDEL NVST: 11.0%, 11.5%, 14.0%, 12.2%, 12.2%, 4.2%, 8.5%, 12.1%, 8.5% NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −60.2% to 34.6%. A gap is a year with no number. A ring marks where a line starts: HIMS, QDEL have no earlier 10-K here.

Return on equity, FY2017 to FY2025

Net income / shareholders' equity at the year end.

−95.0% 98.3% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, -, n/m, n/m, −32.2%, −21.1%, −6.8%, 26.4%, 23.7% HIMS NTRA: n/m, n/m, −44.8%, −47.2%, −72.2%, −77.6%, −56.8%, −15.9%, −12.2% NTRA MEDP: 7.7%, 12.2%, 13.8%, 18.0%, 19.1%, 63.5%, 50.6%, 49.0%, 98.3% MEDP RVTY: 11.7%, 9.2%, 8.1%, 19.5%, 13.2%, 7.7%, 8.8%, 3.5%, 3.3% RVTY BKD: −37.3%, −51.8%, −38.5%, 10.2%, −14.2%, −40.9%, −46.8%, −95.0%, n/m BKD CHE: 18.2%, 34.8%, 30.3%, 35.4%, 43.1%, 31.3%, 24.6%, 27.0%, 27.1% CHE RPRX: -, 30.3%, 38.2%, 9.9%, 6.0%, 0.4%, 11.3%, 8.3%, 7.9% RPRX GMED: 11.1%, 13.2%, 11.1%, 6.8%, 8.6%, 10.3%, 3.1%, 2.5%, 11.8% GMED QDEL: -, -, -, 60.8%, 36.5%, 11.1%, −0.2%, −68.8%, −58.9% QDEL NVST: -, 4.8%, 6.1%, 0.9%, 8.4%, 5.8%, −2.4%, −38.1%, 1.5% NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −95.0% to 98.3%. A gap is a year with no number. A ring marks where a line starts: NVST, HIMS, NTRA, RPRX, QDEL have no earlier 10-K here.

Debt / equity, FY2017 to FY2025

Total debt / shareholders' equity at the year end.

0.00 19.12 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 NTRA: 4.85, 3.84, 0.44, 0.52, 0.51, 0.51, 0.47, 0.07, 0.05 NTRA MEDP: 0.44, 0.13, 0.00, -, 0.00, 0.13, 0.00, -, - MEDP RVTY: 0.80, 0.73, 0.74, 0.53, 0.70, 0.60, 0.50, 0.41, 0.44 RVTY BKD: 3.36, 3.57, 5.11, 4.89, 5.51, 6.61, 9.16, 19.12, n/m BKD CHE: 0.19, 0.15, 0.12, -, 0.30, 0.12, -, -, - CHE RPRX: -, -, 1.02, 0.59, 0.69, 0.75, 0.61, 0.74, 0.92 RPRX QDEL: -, -, -, -, 0.00, 0.54, 0.48, 0.83, 1.40 QDEL NVST: -, 0.00, 0.38, 0.72, 0.43, 0.45, 0.39, 0.51, 0.47 NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 19.12. A gap is a year with no number. A ring marks where a line starts: NVST, RPRX, QDEL have no earlier 10-K here.
CompanyFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
NVST Dec -0.000.380.720.430.450.390.510.47
HIMS Dec --n/mn/m-----
NTRA Dec 4.853.840.440.520.510.510.470.070.05
MEDP Dec 0.440.130.00-0.000.130.00--
RVTY Dec 0.800.730.740.530.700.600.500.410.44
BKD Dec 3.363.575.114.895.516.619.1619.12n/m
CHE Dec 0.190.150.12-0.300.12---
RPRX Dec --1.020.590.690.750.610.740.92
GMED Dec ---------
QDEL Dec ----0.000.540.480.831.40
Peer median0.800.730.590.560.510.540.490.740.68

EPS (diluted), FY2017 to FY2025

Diluted earnings per share, on today's share count after splits.

−$30.54 $19.89 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 HIMS: -, -, −$2.07, −$0.51, −$0.58, −$0.32, −$0.11, $0.53, $0.51 HIMS NTRA: −$2.59, −$2.22, −$1.79, −$2.84, −$5.21, −$5.57, −$3.78, −$1.53, −$1.52 NTRA MEDP: $0.98, $1.97, $2.67, $3.84, $4.81, $7.28, $8.88, $12.63, $15.28 MEDP RVTY: $2.64, $2.13, $2.04, $6.49, $8.08, $4.50, $5.55, $2.20, $2.07 RVTY BKD: −$3.07, −$2.82, −$1.44, $0.44, −$0.54, −$1.25, −$0.84, −$0.89, −$1.12 BKD CHE: $5.86, $12.23, $13.31, $19.48, $16.85, $16.53, $17.93, $19.89, $18.34 CHE RPRX: -, -, -, $1.32, $1.49, $0.10, $2.53, $1.91, $1.78 RPRX GMED: $1.10, $1.54, $1.52, $1.01, $1.44, $1.85, $1.07, $0.75, $3.92 GMED QDEL: -, -, -, $18.60, $16.43, $9.56, −$0.15, −$30.54, −$16.69 QDEL NVST: $2.35, $1.80, $1.60, $0.20, $1.92, $1.37, −$0.60, −$6.50, $0.28 NVST
NVST is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$30.54 to $19.89. A gap is a year with no number. A ring marks where a line starts: HIMS, RPRX, QDEL have no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out NVST and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: NVST's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NVST/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.